SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001144204-19-002677
Filing Date
2019-01-24
Accepted
2019-01-24 17:22:24
Documents
1
Group Members
DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLCXIANGMIN CUI

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D tv511576_sc13d.htm SC 13D 117417
  Complete submission text file 0001144204-19-002677.txt   119216
Mailing Address 201 ELLIOTT AVE. WEST, SUITE 230 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. WEST, SUITE 230 SEATTLE WA 98119 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Subject) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88896 | Film No.: 19540663
SIC: 2834 Pharmaceutical Preparations

Mailing Address UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital China Life Sciences USD Fund III, L.P. (Filed by) CIK: 0001736814 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D